Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer

Completed · Phase 2

Conditions studied: Head and Neck Cancer

In brief

This study will estimate overall response rate of pemetrexed in poor risk patients with advanced, metastatic, or recurrent squamous cell carcinoma of the head and neck.

Key facts

Study ID

NCT00293579

Run by

Ohio State University Comprehensive Cancer Center

People needed

5

Starts

2006-02-01

Expected to finish

2008-11-01

Last updated by the study team

2020-02-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced, metastatic, or recurrent head and neck cancers
• Poor risk patients with ECOG performance status of 2

You may not qualify if…

• Prior treatment for recurrent or metastatic disease
• No clinical or radiological evidence of brain metatases
• Patients with bone only disease are not eligible
• Patients with pleural or peritoneal effusion as only manifestation of diesase

Where it is running

• Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.